Anish Thomas, MBBS, M.D.

Lasker Clinical Research Scholar

Developmental Therapeutics Branch

NCI/CCR

Building 10 Room 4-5330
Bethesda, MD 20892

301-451-8418

anish.thomas@mail.nih.gov

Research Topics

Clinical Interests: Multidisciplinary care of patients with lung cancer, mesothelioma and thymic cancers Research interests: 1. Immunothereapy of malignancy- immunotoxins, vaccines and immune checkpoint regulators 2. Predictive markers for response to biologic therapy 3. Anti-angiogenic and targeted therapeutics 4. Cancer drug development process and clinical trial designs

Biography

Anish Thomas, MD is a medical oncologist who specializes in the treatment of thoracic cancers. He received his medical degree and postgraduate training in Internal Medicine from St. John's Medical College, Bangalore, India, following which he completed residency in Internal Medicine from State University of New York Upstate Medical University, Syracuse. He trained in Medical Oncology and Hematology at the Medical Oncology Branch of National Cancer Institute and the National Heart Lung and Blood Institute, respectively. His clinical care and research efforts are focused on the development of molecularly targeted therapies in thoracic cancers.

Selected Publications

  1. Thomas A, Tanaka M, Trepel J, Reinhold WC, Rajapakse VN, Pommier Y. Temozolomide in the Era of Precision Medicine. Cancer Res. 2017;77(4):823-826.

  2. Del Rivero J, Enewold L, Thomas A. Metastatic lung cancer in the age of targeted therapy: improving long-term survival. Transl Lung Cancer Res. 2016;5(6):727-730.

  3. Thomas A, Chen Y, Berman A, Schrump DS, Giaccone G, Pastan I, Venzon DJ, Liewehr DJ, Steinberg SM, Miettinen M, Hassan R, Rajan A. Expression of mesothelin in thymic carcinoma and its potential therapeutic significance. Lung Cancer. 2016;101:104-110.

  4. Enewold L, Thomas A. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States. PLoS One. 2016;11(6):e0156728.

  5. Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R. Malignant Mesothelioma Effusions Are Infiltrated by CD3<sup>+</sup> T Cells Highly Expressing PD-L1 and the PD-L1<sup>+</sup> Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. J Thorac Oncol. 2016;11(11):1993-2005.


This page was last updated on July 26th, 2017